Choice of Prosthetic Heart Valve in Adults An Update by Rahimtoola, Shahbudin H.
D
w
r
fi
P
e
i
F
O
T
t
c
w
F
M
S
f
A
C
v
c
B
s
a
Journal of the American College of Cardiology Vol. 55, No. 22, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PSTATE-OF-THE-ART PAPER
Choice of Prosthetic Heart Valve in Adults
An Update
Shahbudin H. Rahimtoola, MB, FRCP, DSC (HON)
Los Angeles, California
In the last 7 years, more data have reconfirmed that patients’ comorbid conditions are very important factors
determining patient outcomes. Prosthetic heart valves (PHVs) that require aortic root replacement in the ab-
sence of aortic root disease are associated with poorer outcomes. For the vast majority of patients, the choice of
PHV is between a mechanical valve and a stented bioprosthesis. The choice is largely dependent upon the age
of the patient at the time of PHV implantation and on which complication the patient wants to avoid: specifi-
cally, anticoagulation therapy and its complications with the mechanical valve, and structural valve deterioration
with a bioprosthesis. Data on the pros and cons of the choices and exceptions to the rules are discussed, and a
new algorithm is developed. (J Am Coll Cardiol 2010;55:2413–26) © 2010 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.085e
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w“Not all innovations represent progress.”
—Anonymous
“The feasibility of an operation is not the best indication for its
performance.”
—Lord Cohen of Birkenhead,
at 1950 Moynihan Lecture,
Royal College of Surgeons, England (1)
etermining the choice of a prosthetic heart valve (PHV)
as published 7 years ago (2). In this update, a few issues are
e-emphasized; however, the major thrust is on newer
ndings that have had an impact on the choice of PHV.
atients’ survival after PHV has increased markedly; it is
ssential to consider the patient’s point of view regarding the
deal PHV (Table 1), which should be the goal.
actors Determining
utcomes After PHV Replacement
he Department of Veterans Affairs (VA) randomized trial,
he only randomized trial that determined adjudicated
auses of death (3), showed that 43% to 63% of the deaths
ere not related to the PHV (Table 2). It was previously
rom the Griffith Center, Division of Cardiovascular Medicine, Department of
edicine, LACUSC Medical Center, Keck School of Medicine at University of
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or educational lectures from the American College of Cardiology Foundation,
merican College of Physicians, University of California Los Angeles, University of
alifornia Irvine, Cornell University, Creighton University, Thomas Jefferson Uni-
ersity, Cedars-Sinai Medical Center, Harvard Medical School, University of Wis-
onsin, University of Hawaii, Cardiologists Association of Hong Kong, China, San
ernardino Medical Center, ATS, St. Jude Medical, Carbomedics, Edwards Life-
ciences, Merck, and Pfizer.D
Manuscript received May 31, 2009; revised manuscript received October 23, 2009,
ccepted October 27, 2009.mphasized that “patient-related factors,” now called co-
orbid conditions, were very important in determining
atient outcomes (4). Comprehensive lists of these are
vailable (3–13); those useful in everyday practice are listed
n Table 3.
onclusions. When comparing outcomes with different
HVs, it is important to: 1) ensure that the baseline
haracteristics of the patients and their comorbid conditions
re the same, or are at least very similar, which can be best
etermined by a good prospective randomized trial (14); and
) determine cause of death when comparing survival after
HV replacement.
echanical PHV
andomized trials. The Starr-Edwards valve (Edwards
ifesciences, Irvine, California), a model in use since 1965,
as compared with the St. Jude Medical valve (St. Jude
edical, St. Paul, Minnesota), first used in 1977. For aortic
alve replacement (AVR) and mitral valve replacement
MVR), there were no significant differences in survival,
vent-free survival, and all outcomes (15) (Fig. 1). The
arbomedics valve (Carbomedics, Austin, Texas) was com-
ared with the St. Jude Medical valve. Up to 10 years, there
ere no significant differences in survival and freedom from
omplications after AVR and MVR (16) (Fig. 2).
onrandomized studies. Very long-term studies have
hown good outcomes with virtually no structural valve
eterioration (SVD) with the Starr-Edwards valve up to 40
ears (17), with the Medtronic-Hall valve (Medtronic,
inneapolis, Minnesota) up to 20 and 25 years (18,19),
ith the old Bjork-Shiley valve (Shiley, Irvine, California)
hich incorporated a Delrin ring (DuPont, Wilmington,
elaware), and with St. Jude Medical valves (2).
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Choice of Prosthetic Heart Valve June 1, 2010:2413–26Conclusions. Mechanical PHVs
that are approved by the Food
and Drug Administration (FDA)
and have good and comparable
outcomes at 15 to 20 years of
follow-up will likely have good
outcomes on very long-term
follow-up.
Biological PHVs That Require
Aortic Root Replacement
Biological PHVs that require
aortic root replacement include
stentless and homograft PHV
(both of which can sometimes
be used without replacing the
root), and the Ross principle
(autograft).
Operative mortality. For iso-
lated aortic valve disease without
specific root pathology, using
these 3 types of PHV that re-
quire aortic root replacement is
associated with a higher opera-
ive mortality (9,20,21). Yacoub et al. (22), using selected
ow-risk patients (age 16 years) from Harefield Hospital
n the United Kingdom and Rotterdam, the Netherlands,
eported a low operative mortality with the Ross principle.
hese 2 groups and others analyzed 268 studies of the Ross
rinciple between 2000 and 2008. Of 39 that met entry
riteria, 17 involved adult patients and comprised 1,749
dult patients 18 years of age; their operative mortality
as low (3.12%) (Table 4) (23). In comparison, David (24)
as described 466 patients 50 years of age who had
solated AVR over a period of 20 years with 1 operative
eath (0.2%) (Table 4).
VD. The younger the patient at the time of PHV im-
lantation, the higher the risk of SVD, and SVD of
iological valves should be evaluated with 10 years of
ollow-up (3). At 12 years, the rate of SVD for stentless
orcine valve was 31  4% (25); for patients 65 years of
ge, it was 48  8%; and for patients 65 years of age, it
as 15  4%. The incidence of grade 2 or higher aortic
egurgitation was 52  5%. David (25), arguably the father
f the stentless valve, stated that the Toronto stentless
orcine valve (TSPV) has provided “ . . . suboptimal dura-
ility particularly in patients less than 65 years of age. We
ow use this valve mostly in older patients who have a small
ortic annulus.” The hemodynamics of the TSPV are also
ot better than those of the stented Carpentier-Edwards
C-E) pericardial Perimount valve (Edwards Lifesciences)
see the following text). The rate of SVD for homografts is
imilar to that for bioprostheses (26); at 10 and 15 years, it
as 30  3.8% and 59.7  5.1% (27), and at 13 years in
Abbreviations
and Acronyms
AVR  aortic valve
replacement
C-E  Carpentier Edwards
CHADS2  congestive
heart failure, hypertension,
age >75 years, diabetes
mellitus, prior stroke or
transient ischemic attack
CI  confidence interval
HR  hazard ratio
MVR  mitral valve
replacement
PHV  prosthetic heart
valve
SVD  structural valve
deterioration
TSPV  Toronto stentless
porcine valve
VA  Veterans
Administration
VP-PM  valve prosthesis–
patient mismatchnother study, it was 31.2  6.3% (28).An updated report of the Ross principle in the earlier
otterdam data on 146 patients with a mean follow-up of
.7 years showed the reoperation rate of the autograft at 13
ears was 30.8  6.6%, but for patients 16 years of age, it
as 43.3 9.5% (29); the reoperation rate of the homograft
n the pulmonary position was 12.9 5.5% at 13 years (29).
n another study of 91 younger patients (age 27  10 years;
ange 6 to 49 years), the incidence of autograft dysfunction
t 7 years was 25  8% (30). In a meta-analysis of 39
tudies, 17 studies in adults, the follow-up ranged from only
.8 to 8.7 years and was 5 years in 59% (23). The authors
oncluded, “ The Ross procedure provides satisfactory re-
ults for . . . young adults,” which is questionable. They also
ppropriately concluded, “Durability limitations become
pparent by the end of the post-operative decade, in
articular in younger patients” (23); reality sets in. For
utografts (Ross principle), the rate of SVD at 13 years was
1.2  6.3% (28). Ross’s own data, which have the longest
ollow-up, had reported operative mortality of 7% to 13%
nd reoperation rates of 15% to 52% up to 20 years (31–33).
acoub et al. (22) have warned that reoperation of an
utograft root “is not simply a reoperation. [It is] a risk-
arrying and demanding procedure” because aneurysmatic
scending aorta may be attached to the sternum, the
ulmonary homograft may be compressed by and attached
o the dilated autograft root, and the coronary buttons may
lso pose problems when they are removed from the
utograft and reimplanted in a new root. These procedures
sually require removal of the coronary arteries and reim-
lanting them in the new root. One study reported a 6%
ncidence of perioperative myocardial infarction in patients
ho did not have associated coronary artery disease (34).
onclusions. In 2000, Ross advised the terminology “Ross
rocedure” should not be used because what surgeons are
oing is not what he described; instead, it should be called
he “Ross principle” (35). These procedures are associated
ith a 2- to 3-fold increase of operative mortality (Table 4).
atient’s Point of View of thedeal Prosthetic Heart ValveTable 1 Patient’s P in of View of theIdeal Prosthetic Heart Valve
The valve should:
Provide a cure
Have normal function
Provide normalization, or at least marked improvement of lifestyles
and outcomes
Last a lifetime
PHV implantation should be:
Possible with very low mortality and morbidity
Nondestructive, that is, does not damage other parts of the
cardiovascular system
Duration of hospitalization is short
Can be implanted at a cost that is affordable
Minimal needs for further:
Test(s) and procedure(s)
TherapyCan be inserted percutaneously
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June 1, 2010:2413–26 Choice of Prosthetic Heart Valvehese PHVs are destructive to other cardiovascular struc-
ures and are associated with a significant rate of SVD that
equires complicated reoperation procedures. The SVD rate
s similar to that of porcine bioprostheses. The follow-up
imes were very short, 10 years. One should be very
oncerned about the very likely “high” rate of reoperation
hat will occur beyond 10 years of follow-up, as documented
n the Rotterdam study (29). Moreover, it needs to be
mphasized, 10 years is certainly not a lifetime (36),
articularly for “young” people. These PHVs “should be
eserved for specific root pathology” (9). If used for only
ortic valve disease, pre-operatively one should explain to
he patient: 1) what the procedure involves and that it is not
ust a valve replacement; 2) the risks involved; 3) that young
eople will need multiple reoperations in their lifetime;
) the complexities and risks of reoperation; and 5) that
here are simpler procedures (AVR with stented biopros-
hesis) that are less destructive, less risky, and of more
roven durability. Thus, currently for the overwhelming
ajority of adult patients age 60 to 65 years, the choice of
biological PHV is a stented bioprosthesis. However, there
re exceptions; for example, for active infective endocarditis
ith an associated abscess or uncontrolled infection, a
omograft valve may be chosen (37,38).
echanical Valve Versus Stented Bioprosthesis
andomized trials. Two large trials, the EHVT (Edin-
urgh Heart Valve Trial) (39) and the VA trial (3),
Incidence of Prosthesis-Related Cause of DeathTable 2 Incidence of Prosthesis-Related Cau
Cause of Death
Aortic Valve Replacem
Mechanical Bio
Valve related* 37%
Bleeding† 24%
Sudden death† 35%
*Percent of all deaths. †Percent of valve-related deaths. Data from H
actors Other Than PHV Thatetermine Outcomes After PHV*Table 3 Fa tors Other Than PHV ThatDetermine Outcomes After PHV*
Decade of age
Other valve disease
Complications of PHV
Comorbid conditions
Cardiac
LV dysfunction (systolic and diastolic), heart failure, NYHA functional class III
and IV, CAD, myocardial infarction, CABG, arrhythmias (e.g., atrial
fibrillation), pulmonary hypertension, infective endocarditis
Noncardiac
Impaired renal function (creatinine clearance), renal dialysis, diabetes,
hypertension, dyslipidemia, metabolic syndrome, smoking, liver disease,
lung disease (e.g., COPD)
For operative (30-day mortality), additional factors include emergency surgery  urgent 
lective, previous cardiac surgery, perioperative myocardial infarction, duration of the operation
nd of aortic cross-clamp time, and younger women.
CABG  coronary artery bypass graft; CAD  coronary artery disease; COPD  chronic2
bstructive pulmonary disease; LV  left ventricle; NYHA  New York Heart Association; PHV 
rosthetic heart valve.andomized the comparison of the old Bjork-Shiley (Delrin
ing) valve to a porcine valve. The findings were similar.
fter AVR and MVR, there were no statistically significant
ifferences up to 15 to 20 years after MVR and also after
VR between mechanical and bioprosthesis for systemic
mbolism, valve thrombosis, prosthetic endocarditis, any
alve-relation complication, and also for survival (with 1
xception, discussed in following text). The bleeding rate
as higher among patients with a mechanical valve. In both
rials, there was no SVD with mechanical valves out to 18 to
0 years. In the VA trial, after AVR, use of a mechanical
alve resulted in a lower mortality rate (66  3% vs. 79 
%, p  0.02) (Fig. 3) and a lower reoperation rate (10 
% vs. 25  5%, p  0.004).
The difference became apparent after 10 years. In the VA
rial, SVD occurred mainly among patients 65 years of
ge. After AVR primary valve failure (which is now called
VD) among patients 65 years of age, the SVD was
igher with bioprosthetic valves than with mechanical valves
26  6% vs. 0  0%, p  0.001) but not among patients
65 years of age (9  6% vs. 0  0%, p  0.16) (Table 5).
onrandomized study of older patients. MEDICARE DATA.
edicare data from 1,199 U.S. hospitals undergoing AVR
dentified 111,151 patients who received a bioprosthesis
age 76.7  5.9 years) and 195,903 who received a mechan-
cal valve (age 74.7  6.0 years) from 1991 to 2003 (40).
atients who received bioprostheses had a lower hazard
atio (HR) for death (HR: 0.97; 95% confidence interval
CI]: 0.95 to 0.92), readmission for hemorrhage, stroke or
mbolism (HR: 0.90, 95% CI: 0.88 to 0.92), and death or
eoperation (HR: 0.97, 95% CI: 0.96 to 0.98), but had a
igher hazard ratio for reoperation (HR: 1.25, 95% CI: 1.16
o 1.35). Of importance, overall mortality and complication
ates were20 and10 times higher, respectively, than the
verall reoperation rate.
onclusions. At present, the choice of PHV in most clinical
ituations is between a mechanical PHV and a stented bio-
rosthesis. An important determining factor in the choice
etween these 2 PHVs is which of the 2 complications,
nticoagulation therapy or SVD, one wants to avoid.
omplications of PHVs
ata from the 2 large randomized trials were discussed in
receding text.
onrandomized studies. A review of 70 published series,
f Death
Mitral Valve Replacement
esis Mechanical Bioprosthesis
44% 57%
25% 14%
31% 26%
meister et al. (3).se o
ent
prosth
41%
11%
38%4,202 valves and 132,519 years of follow-up (26), showed
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Choice of Prosthetic Heart Valve June 1, 2010:2413–26here were no significant differences among the various
echanical valves for thromboembolism and also among the
arious bioprosthesis. That was also true for bleeding rates.
nticoagulation therapy. Warfarin (the name comes from
he organization that funded its original research, namely,
isconsin Alumni Research Foundation) has had major
Figure 1 Starr-Edwards Versus St. Jude Medical Mechanical Pr
Data from a prospective randomized trial. Survival after aortic valve replacement (A
(red line) and St. Jude Medical (blue line) mechanical prosthetic heart valve. Ther
shown). Reprinted, with permission, from Murday et al. (15).
Figure 2 Carbomedics Versus St. Jude Medical Mechanical Pro
Data from a prospective randomized trial. There were no significant differences be
to overall patient survival (upper left panel), freedom from valve-related death (up
panel), and patient survival for mitral valve replacement (MVR) only (lower right paeneficial effects. It prevents or reduces the incidence of
alve thrombosis and thromboembolism, especially with
echanical PHV. The disadvantages include lifetime needs
or tests and therapy (Table 1). Moreover, difficulties are
ncountered during initiation of therapy and in maintaining
n adequate international normalized ratio (INR) in the
tic Heart Valves
eft panel) and mitral valve replacement (MVR) (right panel) with Starr-Edwards
also no differences in event-free survival between the 2 types of valves (not
tic Heart Valve
Carbomedics (CM) (red line) and St. Jude Medical (SJM) (blue line) with regard
ht panel), patient survival for aortic valve replacement (AVR) only (lower left
Reprinted, with permission, from Bryan et al. (16). CI  confidence interval.osthe
VR) (l
e weresthe
tween
per rig
nel).
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June 1, 2010:2413–26 Choice of Prosthetic Heart Valveherapeutic range. In the SPORTIF II (Stroke Prevention
sing Oral Thrombin Inhibitor in Atrial Fibrillation) trial
f atrial fibrillation (40,41), over the first 12 weeks, only
4% of the time was the patient’s INR in the therapeutic
ange (INR: 2.0 to 3.0); 38% of the time, the INR was
ubtherapeutic; and 18% of the time, it was above the
herapeutic range. In the Warfarin Compliance Trial (42),
dherence to anticoagulation therapy was a problem. At a
ean follow-up of 32 weeks, the INR was out of range 38%
f the time in the adherent group and 50% of the time in the
onadherent group.
Bleeding is another disadvantage of anticoagulation ther-
py. In the randomized trials of anticoagulation therapy in
trial fibrillation, patients’ average age ranged from 65 to 75
ears in the placebo group, in whom the incidence of major
leeding ranged from 0% to 4.6% per year (2). The
ncidence of minor bleeding was as high as 10.5% per year,
Figure 3 Veterans Administration Randomized Trial
of Mechanical and Bioprosthetic Heart Valves
Data from the Veterans Administration randomized trial. Mortality after aortic
valve replacement (AVR) in patients with mechanical valve (old Delrin ring Bjork-
Shiley [blue line]) and a porcine bioprosthesis (Hancock or Carpentier-Edwards
[red line]) was significantly different only after 10 years of follow-up. Reprinted,
with permission, from Hammermeister et al. (3).
perative Mortality for AVRn Isolat d Aortic Valve DiseaseTable 4 Operative Mortality for AVRin Isolated Aortic Valve Disease
Operative Mortality
Standard AVR
AVR  Root
Reconstruction
STS database* 5.7% 9.2%
UK heart valve registry† 3.6% 10.7%
Single center‡ 2.2% 14.2%
Low-risk patients:
Age 16 yrs
Meta-analysis of Ross principle§ — 3.12%
Age 55 yrs
David 0.2% —
The Society of Thoracic Surgeons (STS), n  409,904 valve procedures (from Rankin et al.
9]). †United Kingdom (UK), n  122,971 valve procedures (from Kalkat et al. [20]). ‡Single
enter, n  215 (from Ali et al. [21]). §Meta-analysis  17 studies from 2000 to 2008; see text
from Takkenberg et al. [23]). David  single center, 466 patients over a 20-year period (from
avid [24]).
AVR  aortic valve replacement.mnd there were some deaths from bleeding (2). The bleeding
ates were obtained with follow-up times of about 2 years;
hus, bleeding rates might be higher if obtained over longer
ollow-up times. Recent data of 13,559 adults with 66,000
erson-years of follow-up in the ATRIA (Anticoagulation
nd Risk Factors in Atrial Fibrillation) study of atrial
brillation showed that the rate of intracranial hemorrhage
ith warfarin therapy offset the benefit of reduction of
schemia for patients65 years of age and for patients 65 to
4 years of age, as well as for patients with CHADS2 (an
cronym for congestive heart failure, hypertension, age 75
ears, diabetes mellitus, and prior stroke or transient isch-
mic attack) score of 0 and 1 (43). In another study of
arfarin therapy for atrial fibrillation, 327 patients 80
ears of age had a higher risk of major bleeding than 456
atients 80 years of age (2.5% vs. 0.9% per year; relative
isk: 1.9, 95% CI: 1.2 to 2.8, p  0.004) (44).
In patients with mechanical valves and the same level of
nticoagulation therapy, at 7 years, patients 60 years of
ge had up to 7 times higher bleeding rates than patients
60 years of age (45). In the Stroke Prevention in Atrial
ibrillation III trial (46) with INR of 2.0 to 3.0, the
ncidence of bleeding was 1.5% per year, which is what one
ould expect with AVR in sinus rhythm according to
linical practice. With MVR, it will be somewhat higher
ecause the INR after MVR is maintained at a higher level
3). Among patients 75 years of age, the bleeding rate is
reatly increased in those with a mechanical valve compared
ith those who received a bioprosthesis, with odds ratio of
8.9 (95% CI: 2.2 to 163.0, p 0.007) (47). In an initiation
tudy of anticoagulation therapy in 472 patients with atrial
brillation 65 years of age (48), in the first year, the
leeding rate ranged from 5.0% to 7.4% per year, intracra-
ial bleed rate was 2.5% per year, and major hemorrhage
mong patients 80 years of age was 13.1% versus 4.7%
mong patients 80 years of age. Furthermore, both bleed-
ng rates and need to be taken off therapy are markedly
ncreased among patients with CHADS2 score of 3
Table 6).
onclusions. Anticoagulants are essential with the use of
rimary Valve Failure* Afterortic Valve Replac men at 15 YearsTable 5 Prim ry Valve Failure* AfterAortic Valve Replacement at 15 Years
All patients
Bioprosthetic valve 23 5%
Mechanical valve 0 0% p 0.0001
Age 65 yrs
Bioprosthetic valve 26 6%
Mechanical valve 0 0% p 0.001
Age 65 yrs
Bioprosthetic valve 9 6%†
Mechanical valve 0 0% p 0.10
Primary valve failure is now called structural valve degeneration (SVD). †The 1 instance of primary
alve failure was actually not due to SVD but was due to reoperation for another cause. Data from
epartment of Veterans Affairs randomized trial (from Hammermeister et al. [3]).echanical valves, and can be instituted and maintained in
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Choice of Prosthetic Heart Valve June 1, 2010:2413–26any patients with low risk. The disadvantages include
ifetime needs of therapy and tests, difficulties in initiating
nd maintaining an adequate INR in many patients, and
ajor risks of bleeding. The risks of bleeding are increased
or patients 65 years of age, greatly so for those 75 years
f age and for those with CHADS2 score 3. For these
atients, warfarin may have to be discontinued for at least a
eriod of time because of bleeding, or because of the need
or noncardiac surgical and nonsurgical procedures that
xpose the patients to the risks of thromboembolism and of
echanical PHV thrombosis, which is associated with heart
ailure, embolism, and mortality (49).
tructural Valve Deterioration
xperimental study. Valve tissue was implanted subcuta-
eously in rats, and calcium content was studied at 90 days
50). The C-E porcine and pericardial Perimount valves had
he lowest calcium levels, 2.13  5.99 g/mg and 3.3 8.4
g/mg dry weight, respectively. Calcium content was much
igher in the Mitroflow pericardial valve (214 11.44, p 
.01), the Medtronic Mosaic porcine valve (25.37  57.68,
 0.02), and the TSPV (244.43  41.74, p  0.01).
linical studies. There is considerable difficulty in obtain-
ng good and comparable data with regard to SVD. The
ain reasons are as follows: 1) both of the large randomized
rials (EHVT and VA) showed that SVD after MVR begins
t about 5 years; and 2) after AVR it begins at about 8 years
3,39). The incidence increases after 10 years, and SVD
fter AVR begins to have a deleterious effect on survival
fter 10 years (3) (Fig. 3). A meta-analysis comprising 5,837
atients (31,874 patient-years of follow-up) with porcine
ioprostheses for AVR showed SVD begins at 8 years and
ncreases greatly after 10 years (Fig. 4) (51). Thus, data with
10 years of follow-up are of limited value for assessing the
ate of SVD unless the rate of SVD between 5 and 10 years
s already unacceptably high. Two, data are often presented
s freedom from reoperation. Reoperation is a movable
arget because reoperation may be performed for causes
ther than SVD, indications for reoperation are often not
rovided, reoperation may not be performed in spite of
resence of SVD, and unless careful follow-up with fre-
trial Fibrillation Study,72 Patients Age >65 YearsTable 6 Atrial Fibrillation Study,472 Patients Age >65 Years
CHADS2
Score
Major Bleed Rate/
100 Person-Years
(95% CI)
Taken Off Therapy Rate/
100 Person-Years
(95% CI)
0 3.12 (0.08–17.38) 15.59 (5.06–36.39)
1 4.28 (1.17–10.96) 17.12 (9.79–27-81)
2 2.04 (0.42–5.96) 12.92 (7.78–20.18)
3 19.54 (10.10–34.13) 32.56 (19.89–50.29)
4 23.24 (8.59–50.97) 35.12 (16.06–66.68)
dapted from Hylek et al. (48).
CHADS2  congestive heart failure, hypertension, age 75 years, diabetes mellitus (1 point for
ach), and prior stroke or transient ischemic attack (2 points); CI  confidence interval.uent echocardiographic/Doppler studies is available, SVDay not be diagnosed. The rate of SVD of bioprothesis is
lso related to the site of PHV implantation.
ortic valve replacement. The incidence of SVD with
tentless porcine valve, homografts, and autografts are
resented in the previous text; their SVD rate is similar to
hat of stented porcine valves (see the following text).
The rate of SVD is not significantly different for various
orcine valves (standard Hancock, Hancock MO, and C-E
orcine valves), including newer valves, and are within the
xpected range of the older porcine valves (51–55) (Fig. 4).
ore recently, very early SVD was documented in 4 of 122
atients at 3, 14, 19, and 44 months after implantation of
edtronic Mosaic porcine bioprostheses, all of whom were
68 years of age at the time of PHV implantation (56). The
-E pericardial Perimount valves have a much lower rate of
VD than the porcine valves (57–64) (Fig. 4).
The VA randomized trial documented that patients 65
ears of age have a significantly lower rate of SVD (Table 5)
2). Studies of homograft, porcine, and pericardial valves
ave confirmed this finding (25–32,51–54,57–66) (Table 7).
ith the Bicor porcine St. Jude Medical valve in patients age
0.8  10.9 years, the reoperation rate for SVD at 20 years
as 38.1  8.5% (67).
With the Mitroflow A12 pericardial bioprosthesis study,
n which 87.5% of 1,513 patients were 65 years of age,
VD at 20 years was 37.7  5.0%, but there was only 1
atient at risk at that time (68). However, at 15 years, SVD
n patients age 50 to 59 years and 60 to 69 years was 40%
value determined from their Fig. 2) (68). In another study,
he SVD of the Mitroflow valve began at about 5 years and
hen increased rapidly among patients 70 years of age and
Figure 4 Actuarial Freedom From
SVD of Porcine and Pericardial PHV
Actuarial freedom from structural valve deterioration (SVD) after aortic prosthetic
heart valve (PHV) implantation. “Porcine limits” (black line) are the limits of SVD
of earlier model stented porcine bioprosthesis, from Grunkemeier et al. (55). “Por-
cine” (blue circles) is from a meta-analysis of later-model stented porcine biopros-
theses, from Puvimanasinghe et al. (51). Carpentier-Edwards (C-E) is from studies
of C-E pericardial Perimount valve (red circles), from Nakajima et al. (60), Banbury
et al. (61), Dellgren et al. (62), Neville et al. (63), Banbury et al. (64), Poirier et al.
(58), and Frater et al. (56). The incidence of SVD is lower with C-E pericardial Peri-
mount valves than with porcine valves.
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June 1, 2010:2413–26 Choice of Prosthetic Heart Valve0 to 74 years of age. The SVD at 15 years was 37.2 
.8%, but there were few patients at risk (69). With the
itroflow A12 pericardial valve, SVD begins very early. 1)
n 1 study, it began at about 5 years and then increased
apidly among patients 70 and 70 to 74 years of age. The
VD at 15 years was 37.2  5.8%, but there were few
atients at risk (69). 2) In another study of patients 79.5 
.1 years of age, SVD began at about 3 to 4 years, and at 10
ears was 18.1  5.4% (70). 3) Among patients 70 years
f age, SVD began at 4 years and was 44.2 2% at 10 years
71). 4) Among patients age 66.5  13.8 years, SVD began
t about 4 to 5 years, was 44.4  6.8% at 10 years, and was
5% at 15 years, but there were few at risk (72). The latter
tudy compared SVD of the Mitroflow valve to the C-E
erimount valve; at 10 years, SVD of the Mitroflow valve
as 44.4  6.8% versus 13.3  4.7% for the C-E Peri-
ount valve (72).
VR. The rate of SVD after MVR is greater than after
VR (26). There is much less information for SVD after
VR than for after AVR. With the Hancock II
Medtronic) porcine valve, the rate of SVD at 20 years for
atients65 years of age was 41 11% versus 73 9% for
atients 65 years of age (65). SVD was diagnosed as
linically relevant valvular stenosis or insufficiency by Dopp-
er echocardiography, reoperation, or autopsy (65). SVD
ith the Bicor porcine bioprosthesis at 13 years was 35.2 
.3%, and at 17 years, it was 20.7% (73). With the C-E
erimount valve after MVR, the SVD rate at 10 years for
atients60 years, 60 to 70 years, and70 years of age was
1.9%, 10.6%, and 0%, respectively (74). After MVR for
atients 60 years of age, SVD at 10 years with the C-E
ericardial valve was 16  3.7% versus the C-E porcine
alve, which was 35.3  3.3% (p  0.05); and SVD at 10
ears for patients 61 to 70 years of age with the C-E
ericardial valve was 4.8  2.1% versus 24.8  3.7% (p 
VD of Bioprosthesis in Younger and Older PatientsTable 7 SVD of Bioprosthesis in Younger and Older Patients
No. First Author (Ref. #) No. of Patients Me
After AVR
1 Banbury et al. (61) 310
2 Neville et al. (63) 787
3 Frater et al. (57) 267
4 Banbury et al. (64) 267
5 Bigliolli et al. (59) 298
6 Borger et al. (65) 1,010
7 Myken and Bech-Hansen (67) 1,518
After MVR
8 Neville et al. (63) 182
9 Myken and Bech-Hansen (67) 194
10 Borger et al. (65) 559
ote: Numbers and percentages are rounded. Numbers 1 to 5 and 8 are with use of Carpentier-Edw
umbers 7 and 9 are with use of Bicor St. Jude porcine valve.
AVR  aortic valve replacement; MVR  mitral valve replacement; SVD  structural valve dete.05) for the C-E porcine valve (75).onclusions. All biological valves are at risk for SVD. The
ge of the patient at the time of PHV implantation is the most
mportant determinant of SVD (3,51,53,54,66) (Table 7).
he risks of major bleeding with mechanical valves and of
eoperation for patients 60 years of age at time of PHV
mplantation were equal at a follow-up time of 12 years (76).
his was confirmed in a more recent review of 3,934
atients (26,467 patient-years of follow-up) (Fig. 5) (77).
ata with the Bicor porcine valve (St. Jude Medical) are
onflicting, and more studies are needed. Data with the
itroflow A12 pericardial valve show that among older
atients, and even among elderly patients, SVD begins very
arly at about 4 to 5 years, and its incidence at 10 years is
igh. The rate of SVD with the C-E Perimount is “low”
ven at long-term follow-up of 15 years, which is a
ignificant advantage of the C-E Perimount valve. An
, yrs
SVD
At Time, yrs Total Age <65 yrs Age >65 yrs
12 18% 24% 7%
12 6% 11% 2%
14 20% 24% 4%
15 23% — 10%
18 47% 64% 16%
20 — 61% 27%
20 26% 73% 41%
12 22% 48% 0%
17 19% 25% 12%
20 — 73% 41%
ricardial Perimount valve. Numbers 6 and 10 are with use of Hancock II (Medtronic) porcine valve.
n.
Figure 5
Comparison of Risks of Reoperation and Major
Bleeding Between Mechanical and Bioprosthetic Heart
Valves Based on Patient Age at Valve Implantation
A plot of the lifetime risks of major bleeding with mechanical valve (blue) and of
reoperation with bioprosthesis (red) depending on age of patient at time of pros-
thetic heart valve implantation. Major bleeding was defined as bleeding requiring
hospitalization or blood transfusions. Data from van Geldorp et al. (77).an Age
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Choice of Prosthetic Heart Valve June 1, 2010:2413–26pproximate incidence of SVD after AVR at 15 to 20 years
ith homografts and bioprosthesis depending on the age at
he time of implantation is shown in Figure 6. In “young”
eople, use of a biological valve will result in reoperation,
robably in multiple reoperations.
ctuarial versus actual. Many studies including some
ited above have cited only data by “actual” method of
nalysis or both actuarial and “actual” method of analysis.
hese 2 methods are very different.
CTUARIAL. The Kaplan-Meier method estimates survival
y censoring patients who have died and assuming the
ifetime span of the survivors will be the same as for those
ho have already died. The Kaplan-Meier method esti-
ates rates of nonfatal events, for example, SVD, by
ensoring patients who have died without SVD. It assumes
atients without SVD (whether alive or dead currently) will
ave SVD in the future at the same rate as those who have
lready had SVD.
CTUAL. The “actual” analysis first described by Starr and
runkemeier (78) censors only patients who are alive
ithout SVD (78,79). It estimates the percentage of pa-
ients who will experience an event.
onsequences. Survival estimates (curves) by the Kaplan-
eier and “actual” methods give “identical results” (79). For
onfatal events, for example, SVD, the Kaplan-Meier
ethod estimates the cumulative incidence of SVD and the
ctual method only provides an estimate of the risk in the
uture for patients who are alive, which should be labeled
Figure 6 SVD of Biological Valves at 15 to 20 Years
Based on Patient Age at Time of PHV Implantation
Shown is the approximate incidence of structural valve deterioration (SVD) at
15 to 20 years in relation to age of patient at the time of prosthetic heart
valve (PHV) implantation with biological valves (homografts and bioprostheses).
Figure was developed after review of data in Yun et al. (66), Takkenberg et al.
(54), van Geldorp et al. (77), Svensson et al. (53), and publications listed in
legend to Figure 4.actual risk” for SVD. Unfortunately, in many publications, mt has been and is being incorrectly labeled as “actual
reedom from SVD.” “Actual freedom” is not a statistical
erm (80). The definition of actual in English is “existing in
act; real” (81,82), and the actual method provides a value
hat neither exists in fact nor is real. The statistical aspects
f the actual method have been discussed in an editorial and
etters to the editors by statisticians and their colleagues
80,83,84). Two journals have stated they will no longer
ublish “actual freedom” results in articles reporting long-
erm intrinsic performance of PHV (80).
Many comorbid conditions listed in Table 3 contribute
o, or are a cause of, both death and nonfatal events, and
hus contribute to both of the “competing risks” (death and
onfatal events), but very few publications provide data on
hese comorbid conditions. Clinicians and clinical investi-
ators must also recognize another major problem is accu-
ate determination of the cause of death. With the actual
ethod, all patients who had died are excluded; therefore,
ne has to be sure deaths that occurred were not due to
VD, and/or that SVD did not significantly contribute to
he death. For example, SVD may lead to heart failure that
aused death, but the death may be attributed to heart
ailure and not to SVD. Furthermore, even if the patient
ied of another cause, he or she could also have had SVD,
hich would not be detected unless the patient had an
ppropriate imaging technique shortly before demise or had
careful autopsy performed. In the Butchart et al. (18)
tudy, autopsies were performed for 48% of all deaths and
or 70% of sudden or unwitnessed death. At present,
utopsy rates have declined to abysmally low rates. Diagno-
is of causes of death is a moving target and potentially
ubject to considerable, even if unintentional, bias. In the
A randomized trial (3), causes of death were determined
y an independent blinded committee (adjudicated), which
ay be the best that is possible at the present time.
onclusions. 1) Studies showing better survival by the
ctual method than by actuarial method have problems in
he calculations. 2) To obtain values of event rates for SVD,
he Kaplan-Meier method should be used, and even if the
anuscript states “actual freedom from SVD,” the actual
ethod does not provide this information. 3) If one is
ertain about the absence of nonfatal events including SVD
mong patients who died, then the actual method provides
n estimate of the “actual risk” in the future but not
freedom from.” 4) The concept of actual risk is still relevant
ut its misuse and difficulties of an accurate estimate
uggests it should not be used. 5) Reoperation for SVD
ost likely underestimates SVD rates.
ize of PHV
oes size matter? Yes, provided the PHV size is measured
fter endothelialization and tissue in-growth is more or less
omplete; that is, at 6 months and 12 months after PHV
mplantation (85,86). After AVR, valve prosthesis-patientismatch (VP-PM) (87), if mild, usually has no impact on
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June 1, 2010:2413–26 Choice of Prosthetic Heart Valveatient outcomes; if moderate, usually the patient is asymp-
omatic or is symptomatic with associated conditions or it
ecomes severe due to thrombus and/or pannus; and if
evere, is associated with significant limitations (86) and
educed survival (88). For definition of severity of VP-PM,
ee Table 8. Severe VP-PM should be avoided, and that is
articularly important if pre-operative LV function is re-
uced. In such patients, aortic root enlargement can be
erformed at comparatively low risk by experienced and
killed cardiovascular surgeons.
Is there a perfect method to predict VP-PM pre-
peratively? No. A study of 383 patients with echocardiog-
aphy at 6 months after AVR (89) showed the best method
o predict it pre-operatively was by PHV areas obtained in
normal” PHV from echocardiography at 6 months after
HV replacement in their own laboratory. It had a sensi-
ivity of 53% and specificity of 83%, and it reduced the
ncidence of VP-PM from 8.7% to 0.8% (p 0.003). It was
etter than other methods based on in vitro data, manufac-
urer charts, and reference echocardiographic data in the
iterature. After MVR, severe VP-PM is associated with a
orse outcome (90–92).
alve Areas With Use of Various PHV
echanical Versus Bioprosthesis
andomized trial. In the VA randomized trial, cardiac
atheterization data 6 months after PHV implantation (85)
howed there were no significant differences in PHV areas
etween the Bjork-Shiley valve and porcine valves in valve
izes 21 to 29 mm.
ioprosthesis Versus Bioprosthesis
n vitro hydrodynamics. The C-E Perimount valve was
ompared with 7 other bioprosthetic valves. At a flow rate of
l/min and a heart rate of 70 beats/min, the C-E had lower
ressure drop (gradient) and larger valve areas in valve sizes
9 to 29 mm (93). With a bileaflet mechanical PHV valve
ize 21 mm at a flow rate of 4 l/min, the St. Jude Medical
egent-19 and the Sorin Bicarbon Slimline had larger
ffective valve orifice areas than the ATS 18 mm, On-X 19
everity of VP-PMTable 8 Severity of VP-PM
Severity of VP-PM after AVR PHV area, cm2/m2*
Mild 0.9
Moderate 0.6 to 0.9
Severe 0.6
Severity of VP-PM after MVR PHV area, cm2*
Very mild 2.0
Mild 1.5 to 2.0
Moderate 1.1 to 1.5
Severe 1.0
Reprinted with permission from Rahimtoola (2).
PHV  prosthetic heart valve; VP-PM  valve prosthesis-patient mismatch; other abbreviations
s in Table 7.m, and Carbomedics Top Hat (p 0.005) (94). The C-E
(erimount valve was compared with the Medtronic Mosaic
alve in sizes 21, 23, and 25 mm. At cardiac outputs of 2 and
l/min, the C-E valve had higher transvalvular resistance.
owever, at cardiac output of 4.1 to 9.0 l/min (at normal
ardiac indexes), the C-E Perimount valves had very much
ower resistances than the Medtronic Mosaic valves (95,96).
n vivo hemodynamics. “Normal” Doppler echocardio-
raphic values of prosthetic aortic valves have been
isted (97).
andomized trials. Data are shown in Table 9 (98–102).
onclusions. There is no significant difference in valve
reas at 6 months between a bileaflet mechanical valve and
orcine bioprosthesis for valves with the same valve size.
he stented C-E Perimount valve has similar PHV area as
he TSPV. The C-E Perimount valve has a lower rate of
VD up to 15 to 20 years of follow-up and has larger PHV
rea than other bioprostheses. The C-E Perimount magna
as an even larger valve area than the C-E Perimount valve.
hoosing a PHV for an Individual Patient
he physicians involved in the decision-making process
hould be very knowledgeable about the patient outcomes
ith the use of the various PHV discussed above and also
reviously (2), and they should be completely discussed with
he patient. The final choice of PHV should be a joint
ecision by patient, cardiologist, and cardiac surgeon.
Patients with a PHV have a less than normal life
xpectancy, especially the young (76,77,102–105). Several
ssues should be kept in mind while choosing a PHV for an
ndividual patient (Table 10). A very important factor is the
ge of the patient. The older patients (55 to 60 years of
ge for AVR and probably60 to 65 years of age for MVR)
ave a shorter life expectancy, higher or very high risk of
HV Areas From Randomized In Vivo TrialsTable 9 PHV Areas From Randomized In Vivo Trials
PHV Size
(mm)
PHV Area Index
(cm2/m2) p Value
(A) Medtronic Mosaic 23 0.74 0.06
C-E Perimount 23 0.79 0.08 0.05
Medtronic Mosaic 25 0.80 0.09
C-E Perimount 25 0.85 0.09 0.05
(B) C-E Perimount Magna 1.17 0.27
C-E Perimount 0.94 0.36 0.01
Medtronic Mosaic porcine 0.83 0.23 0.001
Soprano valve 0.87 0.20 0.004
(C) C-E Perimount 22.9 2.0 1.9 0.09
Toronto stentless porcine 26.3 2.0 1.74 0.66 NS
(p  0.0001)
(D) C-E Perimount 24.8 2.17 0.9 0.2 NS
Toronto stentless porcine 24.8 2.51 0.88 0.22
(E) C-E Perimount Magna 23.4 2.1 1.07 0.4
C-E Perimount 22.4 1.8 0.80 0.2
C-E Prima plus 24.3 1.7 0.87 0.3 0.028
A) From Walther et al. (98). (B) Supraannular position in patients with small aortic annulus (21 to
3 mm); from Botzenhardt et al (99). (C) From Cohen et al. (100). (D) From Chambers et al. (101).
E) From Totaro et al. (102).
C-E  Carpentier-Edwards; NS  not significant; PHV  prosthetic heart valve.
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Choice of Prosthetic Heart Valve June 1, 2010:2413–26leeding with anticoagulant therapy, but fortunately, a
ower incidence of SVD. At age 55 years with AVR, risks of
leeding with mechanical valves and of reoperation with
ioprosthetic valves are equal (77) (Fig. 5). Furthermore,
ith AVR, patients 60 years of age have a better life
xpectancy with a bioprosthesis than with a mechanical
alve (Fig. 7) (40,77). Thus, a stented bioprosthesis is the
HV of first choice for older patients. The younger the
atient, the greater the risk of SVD (Fig. 6) and of
eoperation; there is also a possibility of the need for
ultiple reoperations with a biological valve. Thus, a
echanical valve is a PHV of first choice for younger
atients. However, certain subgroups of young patients with
ery low expected survival, for example, continuing intrave-
ous drug abusers and patients on dialysis, who have a 45%
nd 85% mortality rate by 1 and 5 years, respectively (12),
ne may choose a bioprosthetic valve. Other factors, for
xample, patient wishes and expectations, are also very
mportant in choice of PHV, and are listed in Table 10.
The issue of choice of PHV for young women who desire
o be pregnant was reviewed in 2003 (106) and was updated
n 2007 (107). It is a complex issue associated with multiple
actors and is beyond the scope of this manuscript.
actors to be Consideredn the Decision for Choice of PHVTable 10 Factors to be Consideredin the Decision for Choice of PHV
Age of the patient
Comorbid conditions: cardiac and noncardiac
Expected life span of patient
Use of a PHV
That does not require “root replacement” for isolated aortic valve disease
With long-term follow-up outcomes that are at least as “good” as the best of
the available PHV
With which individual physicians and medical centers have the necessary skill
and experience
Probability of adherence and compliance with warfarin therapy
Patient’s wishes and expectations
Other extenuating circumstances
HV  prosthetic heart valve.
Figure 7 EFLE After AVR Based on Patient Age at Valve Implan
Event-free life expectancy (EFLE) after aortic valve replacement (AVR) in the U.S. w
of patient at time of valve implantation. Included are 68% upper (u) and lower (l) c
age, and probably so for patients 55 years of age (see also Fig. 5). Reprinted, witA suggested algorithm for choice of PHV for AVR and
VR is shown in Figure 8. The choice between the 2 types
f PHV (mechanical or biological) is dependent upon which
omplication one wants to avoid or reduce to a minimum.
ny mechanical PHV approved by the authorized agency of
ach country (FDA in the U.S.) and with documented good
utcomes to 15 to 20 years of follow-up is acceptable for
hat country. Biological valves that need aortic root replace-
ent (stentless, homograft, Ross principle) should not be
sed unless aortic root replacement is necessary for root
isease. An exception is the homograft for active infective
ndocarditis with abscess or uncontrolled infection. Stented
ioprostheses (porcine or pericardial) are the biological valve
f choice. SVD with the Mitroflow A12 pericardial valve
egins very early even in older patients, and at 10 years is
igh and greater than with the C-E Perimount valve. At
resent, the C-E Perimount valve has a documented “low”
ate of SVD with follow-up of10 years (Fig. 4). It also has
more favorable hemodynamic profile, which is best with
he C-E Perimount magna.
Some circumstances that would be exceptions to this
lgorithm include the following. 1) Bioprosthetic SVD is
ot reduced suddenly at 60 years for AVR and 65 years for
VR. Thus, if the patient is willing to accept a “small”
ncreased risk of SVD (Fig. 6) if a bioprosthetic PHV were
o be implanted 5 years earlier for benefit of not needing
nticoagulant treatment with use of mechanical PHV, then
he decision to insert a bioprosthetic PHV at that age may
e reasonable. 2) In certain circumstances, even though the
atient needs anticoagulant therapy for other indications
uch as atrial fibrillation, it may still be preferable to insert
bioprosthetic valve. For example, a patient 65 to 75 years
f age who has atrial fibrillation is at an increased risk of
hromboembolism but may also be at increased or greatly
ncreased risk of bleeding with anticoagulant therapy. If
leeding requires discontinuing warfarin therapy for an
xtended period, then this puts the mechanical valve at
erious risk of thrombosis and thromboembolism; therefore,
n
chanical prosthesis (MP) (red) and bioprosthesis (BP) (blue) depending on age
nce limits (CL). The EFLE is better with bioprosthesis for patients 60 years of
ission, from van Geldorp et al. (77).tatio
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June 1, 2010:2413–26 Choice of Prosthetic Heart Valvene should consider insertion of a bioprosthetic PHV. This
robably also applies to the patient who already has a
echanical valve at another site, especially if the other site
eeds a lower INR level. Any reduction of risks of PHV
hrombosis and thromboembolism is reasonable; also note
he shorter life expectancy of these patients. 3) The need for
eoperation in older patients for SVD must be kept in
erspective. Life expectancy after aortic PHV implantation
t age 60, 65, 70, and 75 years are 15, 12, 10, and 7 years,
espectively; the risks of SVD at these times is 25%, 18%,
0%, and 5%, respectively (77). Thus, if 100 patients had
HV initially, the number of patients who will need
eoperation in these age groups will be 4, 3, 1, and 1,
espectively. 4) The survival of patients after MVR is lower
han that after AVR (108). For patients 65 years of age who
eed MVR and anticoagulation therapy for another reason,
he necessity of reoperation on these patients at age 80 years
s small. For patients who had AVR or MVR at age 61 to
0 years, the probability of being alive at 15 years was 30.9%
fter AVR and 16.1% after MVR (108). The probability of
VD at this age is 20% (105). If initially 100 patients had
VR with a bioprosthesis, of the initial 100 patients who
ad AVR, only 6 will need reoperation. If initially 100
atients had MVR with a bioprosthesis, of the initial 100
atients, only 3 will need reoperation. With AVR or MVR
t age70 years, the probability of being alive 15 years later
s 16.1% and 2.8%, respectively (108). If the rate of SVD is
10% in this age group (77), then of the initial 100 patients
ho had AVR or MVR, 2 and 1, respectively, will need
Figure 8 Algorithm for Choice of Prosthetic Heart Valve
An algorithm for choice of prosthetic heart valve. Adapted and modified from Rahim
A/C  anticoagulation; AVR  aortic valve replacement; INR  international normeoperation.Implantation of PHV has had greatly beneficial effects for
atients with valvular heart disease and has had an enor-
ous positive impact over the last century on the manage-
ent of these patients (109). However, it is not a curative
rocedure and is associated with complications. The patient
as to understand and accept the risks, which should be
arefully and patiently explained to them because the patient
s taking all the risks, and not the physicians.
eprint requests and correspondence: Dr. Shahbudin H. Ra-
imtoola, University of Southern California, 1200 North State
treet, Old GNH, Room 7131, Los Angeles, California 90033.
-mail: rahimtoo@usc.edu.
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